anti-CD19 CAR/anti-NY-ESO-1 TCR T-cell therapy (The First Affiliated Hospital of Zhengzhou University/Beijing Chineo)

N/A

Report date: 2025/03/14 16:24:55

Base Information

Drug Nameanti-CD19 CAR/anti-NY-ESO-1 TCR T-cell therapy (The First Affiliated Hospital of Zhengzhou University/Beijing Chineo)
Drug Alias Nameenhanced precision TCR-T-cell therapy (The First Affiliated Hospital of Zhengzhou University/Beijing Chineo)anti-CD19 CAR-TCR-T-cell therapy (The First Affiliated Hospital of Zhengzhou University/Beijing Chineo)dual anti-CD19 CAR-T cell therapy/anti-NY-ESO-1 TCR T-cell therapy (The First Affiliated Hospital of Zhengzhou University/Beijing Chineo)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsHuman leukocyte antigen modulatorsCancer/testis antigen 1 modulators
TargetsB-lymphocyte antigen CD19Cancer/testis antigen 1Human leukocyte antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesThe First Affiliated Hospital Of Zhengzhou University
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Chineo Medical Technology Co LtdThe First Affiliated Hospital Of Zhengzhou University
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A